Cure GM1 Foundation provides all programs, services, and support to individuals and families affected by GM1 gangliosidosis without discrimination on the basis of race, color, national origin, ethnicity, religion, sex, gender identity or expression, sexual orientation, age, disability, genetic information, socioeconomic status, immigration status, or any other characteristic protected by applicable federal, state, or local law.
Because GM1 gangliosidosis is a genetic disease affecting individuals across all populations and at the earliest stages of life, our commitment to equitable access is foundational to our mission. We recognize that families navigating a rare, progressive neurological diagnosis may face compounding barriers, including limited English proficiency, geographic isolation, financial hardship, and the disability-related needs of the affected individual themselves. We are committed to ensuring that these barriers do not determine who receives our support.
Cure GM1 Foundation will make reasonable accommodations to ensure meaningful access to our services for individuals with disabilities and for those with limited English proficiency. No individual or family will be excluded from, denied the benefit of, or subjected to discrimination under any program or activity we administer.
Clinical trials and clinical trial enrollment are controlled by the sponsors of clinical trials and do involve specific inclusion and exclusion criteria as required by the government for clinical research.